• Lucatumumab
    Lucatumumab (CHIR 12.12 or HCD122) is a human monoclonal antibody against CD40 development of which was discontinued by Novartis in 2013 after it was...
    6 KB (456 words) - 23:22, 31 December 2023
  • Thumbnail for Tumor necrosis factor
    Tumor necrosis factor
    Dacetuzumab Denosumab Drozitumab Enavatuzumab Iratumumab Lexatumumab Lucatumumab Mapatumumab Oxelumab Ruplizumab Tabalumab Tavolixizumab Teneliximab Tigatuzumab...
    49 KB (6,232 words) - 07:00, 22 October 2024
  • List of drugs: Ls–Ly
    lubeluzole (INN) lubiprostone (USAN) lucanthone (INN) lucartamide (INN) lucatumumab (USAN) Lucentis lucimycin (INN) lucinactant (USAN) Ludiomil lufenuron...
    3 KB (218 words) - 20:57, 27 August 2024
  • Thumbnail for List of therapeutic monoclonal antibodies
    List of therapeutic monoclonal antibodies
    dermatitis in dogs Lorvotuzumab mertansine mab humanized CD56 cancer Lucatumumab mab human CD40 multiple myeloma, non-Hodgkin's lymphoma, Hodgkin's lymphoma...
    137 KB (4,083 words) - 21:25, 19 October 2024
  • Thumbnail for Tumor necrosis factor superfamily
    Tumor necrosis factor superfamily
    Dacetuzumab Denosumab Drozitumab Enavatuzumab Iratumumab Lexatumumab Lucatumumab Mapatumumab Oxelumab Ruplizumab Tabalumab Tavolixizumab Teneliximab Tigatuzumab...
    8 KB (316 words) - 13:53, 10 September 2024
  • Thumbnail for TNF receptor superfamily
    TNF receptor superfamily
    Dacetuzumab Denosumab Drozitumab Enavatuzumab Iratumumab Lexatumumab Lucatumumab Mapatumumab Oxelumab Ruplizumab Tabalumab Tavolixizumab Teneliximab Tigatuzumab...
    8 KB (501 words) - 13:55, 10 September 2024
  • Thumbnail for Lymphotoxin alpha
    Lymphotoxin alpha
    Dacetuzumab Denosumab Drozitumab Enavatuzumab Iratumumab Lexatumumab Lucatumumab Mapatumumab Oxelumab Ruplizumab Tabalumab Tavolixizumab Teneliximab Tigatuzumab...
    24 KB (2,809 words) - 11:12, 20 August 2024
  • Thumbnail for Tumor necrosis factor receptor 2
    Tumor necrosis factor receptor 2
    Dacetuzumab Denosumab Drozitumab Enavatuzumab Iratumumab Lexatumumab Lucatumumab Mapatumumab Oxelumab Ruplizumab Tabalumab Tavolixizumab Teneliximab Tigatuzumab...
    12 KB (1,387 words) - 13:47, 4 September 2024
  • Thumbnail for Tumor necrosis factor receptor 1
    Tumor necrosis factor receptor 1
    Dacetuzumab Denosumab Drozitumab Enavatuzumab Iratumumab Lexatumumab Lucatumumab Mapatumumab Oxelumab Ruplizumab Tabalumab Tavolixizumab Teneliximab Tigatuzumab...
    20 KB (2,146 words) - 16:24, 21 August 2024
  • Pegipanermin
    Dacetuzumab Denosumab Drozitumab Enavatuzumab Iratumumab Lexatumumab Lucatumumab Mapatumumab Oxelumab Ruplizumab Tabalumab Tavolixizumab Teneliximab Tigatuzumab...
    5 KB (305 words) - 05:22, 23 October 2024
  • Thumbnail for Lymphotoxin beta
    Lymphotoxin beta
    Dacetuzumab Denosumab Drozitumab Enavatuzumab Iratumumab Lexatumumab Lucatumumab Mapatumumab Oxelumab Ruplizumab Tabalumab Tavolixizumab Teneliximab Tigatuzumab...
    12 KB (1,494 words) - 19:35, 4 September 2024
  • Minretumomab
    Intetumumab§ Ipilimumab Iratumumab§ Istiratumab Icrucumab§ Lexatumumab§ Lucatumumab§ Mapatumumab§ Narnatumab§ Necitumumab Nesvacumab§ Nivolumab# Ofatumumab...
    5 KB (368 words) - 15:29, 21 August 2024
  • Thumbnail for Lymphotoxin beta receptor
    Lymphotoxin beta receptor
    Dacetuzumab Denosumab Drozitumab Enavatuzumab Iratumumab Lexatumumab Lucatumumab Mapatumumab Oxelumab Ruplizumab Tabalumab Tavolixizumab Teneliximab Tigatuzumab...
    12 KB (1,508 words) - 17:56, 19 August 2022
  • Lymphotoxin
    Dacetuzumab Denosumab Drozitumab Enavatuzumab Iratumumab Lexatumumab Lucatumumab Mapatumumab Oxelumab Ruplizumab Tabalumab Tavolixizumab Teneliximab Tigatuzumab...
    12 KB (1,459 words) - 03:14, 30 October 2022
  • Thumbnail for Naptumomab estafenatox
    Naptumomab estafenatox
    Intetumumab§ Ipilimumab Iratumumab§ Istiratumab Icrucumab§ Lexatumumab§ Lucatumumab§ Mapatumumab§ Narnatumab§ Necitumumab Nesvacumab§ Nivolumab# Ofatumumab...
    4 KB (241 words) - 13:42, 14 July 2024
  • Indium (111In) altumomab pentetate
    Intetumumab§ Ipilimumab Iratumumab§ Istiratumab Icrucumab§ Lexatumumab§ Lucatumumab§ Mapatumumab§ Narnatumab§ Necitumumab Nesvacumab§ Nivolumab# Ofatumumab...
    3 KB (129 words) - 01:04, 19 July 2023